Global Lacrimal Devices Industry Poised to Reach US$39.7 Million with a 5.5% CAGR by 2029, | as Revealed by FMI

The Global Lacrimal Devices Industry is on an upward trajectory, with a projected value of US$ 39.7 million anticipated by the end of 2029, boasting a robust 5.5% Compound Annual Growth Rate (CAGR). This growth follows a market value of approximately US$ 25.6 million in 2021.

Lacrimal devices, such as Nasolacrimal stents, represent a breakthrough in ophthalmic care, offering a novel pathway for tear drainage in cases where conventional tear ducts are nonfunctional, and alternative drainage options are limited. The concept of lacrimal stents was introduced by Dr. Graue in 1932, using silver wire as the primary material.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-9649

Over the years, the lacrimal devices landscape has witnessed significant advancements, with various materials like silk, nylon, polyethylene, and polypropylene being employed to enhance performance and patient comfort. These small tubes are typically constructed from silicone or other semi-rigid yet flexible materials, featuring an open center lumen for optimal tear drainage.

The Global Lacrimal Devices Industry’s impressive growth can be attributed to ongoing innovations and increasing demand for effective tear drainage solutions. With a 5.5% CAGR driving the market’s expansion, it is clear that lacrimal devices are becoming an integral part of the ophthalmic industry, offering hope and improved quality of life to countless individuals worldwide.

The increased demand for ophthalmic treatments with greater success rates and minimum intrusions, as well as an increase in patients with nasolacrimal duct obstruction, are driving the Global Lacrimal Devices Industry.

During the projected period, the introduction of innovative and high-success-rate treatments will move the market forward. The adoption of precise and updated lacrimal devices, such as the new lacrimal cannula, which combines flexibility and strength to prevent trauma by providing easy access to the canaliculus, is a fundamental driver of market expansion.

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-9649

Manufacturers Emphasizing Advanced Product Development

Numerous organizations are focusing on new product development for lacrimal duct stent tubes. In June 2019, FCI Ophthalmic offered a complete line of BIKA stents namely, BIKA, BIKA for DCR, and Infant BIKA covering a range of sizes that will benefit most of the congenital nasolacrimal duct obstruction (CNLDO) and dacryocystorhinostomy (DCR) cases.

Key Takeaways – Lacrimal Duct Stent Tube Market Study

• Bicanalicular lacrimal duct stent tube is expected to contribute a fourth of the revenue share in the lacrimal duct stent tube market owing to its high success rate in stent placement.
• Hospitals captured the maximum share of the lacrimal duct stent tube market owing to the highest patient footfall followed by ophthalmic clinics.
• Attributed to the growing patient pool for retinal diseases, especially due to premature births, contributed to the dominance of North America in the lacrimal duct stent tube market.
• Increasing awareness for the availability of the treatment for nasolacrimal duct stent obstruction among caregivers of prematurely born babies and an increasing number of skilled professionals are expected to drive the growth of the lacrimal duct stent tube market in East Asia.

Examining the study’s underlying assumptions. Ask an Analyst
https://www.futuremarketinsights.com/ask-question/rep-gb-9649

Competitive Landscape

• FCI Ophthalmics
• Kaneka Corporation (Kaneka Pharma America LLC)
• Gunther Weiss Scientific Glass
• Bess Medizintechnik GmBH

Key Market Segments Covered In Global Lacrimal Devices Industry Research

By Product:

• Monocanalicular Lacrimal Duct Stent Tube
• Bicanalicular Lacrimal Duct Stent Tube

By End User:

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube